psoriasis

AbbVie gets its first approval for a drug execs believe could be worth up to $5B in annual sales
AbbVie gets its first approval for a drug execs believe could be worth up to $5B in annual sales
Endpoints
AbbVie
Japan
psoriasis
risankizumab
Skyrizi
Flag link:
AbbVie's immunology blockbuster-to-be Skyrizi picks up first global approval
AbbVie's immunology blockbuster-to-be Skyrizi picks up first global approval
Fierce Pharma
AbbVie
Japan
Skyrizi
psoriasis
psoriatic arthritis
Flag link:
4 Blockbuster Drug Launches to Watch in 2019
4 Blockbuster Drug Launches to Watch in 2019
Motley Fool
drug launches
AbbVie
Alexion Pharmaceuticals
Aimmune Therapeutics
Skyrizi
psoriasis
Upadacitinib
rheumatoid arthritis
Ultomiris
PNH
AR101
peanut allergy
Flag link:
Novartis data confirm rapid response and high efficacy of Cosentyx in psoriasis patients for first time in China
Novartis data confirm rapid response and high efficacy of Cosentyx in psoriasis patients for first time in China
Pharmaceutical Business Review
Novartis
Cosentyx
China
psoriasis
Flag link:
Novartis Sues Janssen Over False Advertisements for Psoriasis Drug
Novartis Sues Janssen Over False Advertisements for Psoriasis Drug
RAPS.org
Novartis
Janssen
JNJ
psoriasis
false advertising
Tremfya
Flag link:
Johnson & Johnson keeps the heat on Tremfya's rivals with at-home injector nod
Johnson & Johnson keeps the heat on Tremfya's rivals with at-home injector nod
Fierce Pharma
JNJ
Janssen
Tremfya
psoriasis
Novartis
Cosentyx
Eli Lilly
Taltz
Flag link:
FDA approves J&J’s Tremfya self-injection pen for psoriasis
FDA approves J&J’s Tremfya self-injection pen for psoriasis
Drug Delivery Business News
JNJ
FDA
Tremfya
psoriasis
Flag link:
J&J still sees plenty of opportunity in crowded immunology markets—starting with psoriasis
J&J still sees plenty of opportunity in crowded immunology markets—starting with psoriasis
Fierce Pharma
JNJ
JPMHC 2019
immunology
psoriasis
Tremfya
Flag link:
Microbiome Report for Week Ending 12/1/18
Microbiome Report for Week Ending 12/1/18
CP Wire
microbiome
Evelo Biosciences
Kaleido Biosciences
Vedanta Biosciences
psoriasis
atopic dermatitis
IBD
Flag link:
Microbiome Report for Week Ending 12/1/18
Evelo Biosciences
Kaleido Biosciences
Vedanta Biosciences
psoriasis
atopic dermatitis
IBD
Flag link:
Bausch Health announces good Phase III results from psoriasis therapy
Bausch Health announces good Phase III results from psoriasis therapy
GoinPharma
Bausch Health
psoriasis
clinical trials
Bryhali
Flag link:
Bristol-Myers Squibb’s Psoriasis Drug Dazzles in Phase II Clinical Trial
Bristol-Myers Squibb’s Psoriasis Drug Dazzles in Phase II Clinical Trial
BioSpace
Bristol-Myers Squibb
BMS-986165
psoriasis
clinical trials
Flag link:
MC2 Therapeutics' psoriasis drug succeeds in Phase 3 trial
MC2 Therapeutics' psoriasis drug succeeds in Phase 3 trial
Biopharma Dive
MC2 Therapeutics
clinical trials
psoriasis
MC2-01
Taclonex
Flag link:
Dermavant inks $330M deal for GSK's phase 3-ready psoriasis drug
Dermavant inks $330M deal for GSK's phase 3-ready psoriasis drug
Fierce Biotech
GSK
Dermavant
Roivant
CSO
tapinarof
psoriasis
atopic dermatitis
Flag link:
Skin treatment device-maker Clarify Medical raises $1m
Skin treatment device-maker Clarify Medical raises $1m
Mass Device
Clarify Medical
devices
psoriasis
Flag link:
Valeant shares drop 5% after FDA fails to approve plaque psoriasis lotion
Valeant shares drop 5% after FDA fails to approve plaque psoriasis lotion
Marketwatch
Valeant Pharmaceuticals
psoriasis
FDA
Duobrii
Flag link:
Johnson & Johnson’s Tremfya Approved for Reimbursement in the UK and Germany
Johnson & Johnson’s Tremfya Approved for Reimbursement in the UK and Germany
CP Wire
JNJ
NICE
Tremfya
psoriasis
Flag link:
Johnson & Johnson’s Tremfya Approved for Reimbursement in the UK and Germany
JNJ
Tremfya
psoriasis
Flag link:
Two drugs in the pipeline representing unique marketing challenges
Two drugs in the pipeline representing unique marketing challenges
Medical Marketing and Media
valrox
Biomarin
hepatitis A
risankizumab
AbbVie
Boehringer Ingelheim
psoriasis
Flag link:
US approves UCB’s Cimzia for psoriasis
US approves UCB’s Cimzia for psoriasis
Pharma Times
FDA
UCB Pharma
Cimzia
psoriasis
Flag link:

Pages